Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia

Leukemia

Volumn 23, Issue 3, 2009, Pages 545-556

  Rocha, V ^a   Porcher, R ^a   Fernandes, J F ^a   Filion, A ^a   Bittencourt, H ^a   Silva Jr , W ^b   Vilela, G ^a   Zanette, D L ^b   Ferry, C ^a   Larghero, J ^a   Devergie, A ^a   Ribaud, P ^a   Skvortsova, Y ^a   Tamouza, R ^a   Gluckman, E ^a   Socie, G ^a   Zago, M A ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450 2B6; GLUTATHIONE TRANSFERASE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; VITAMIN D RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG METABOLISM; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HLA MATCHING; HUMAN; HUMAN CELL; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; SIBLING; SIDE EFFECT; STOMATITIS;

EID: 62549147068     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.323     Document Type: Article

References (59)

1. Evans WE, Johnson JA. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9-39.
2. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 2004; 127: 479-490.
3. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
4. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graftversus- host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94: 3941-3946.
5. Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ et al. Relation of an interleukin-10 promoter polymorphism to graftversus- host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349: 2201-2210.
6. Rocha V, Franco RF, Porcher R, Bittencourt H, Silva Jr WA, Latouche A et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100: 3908-3918.
7. Socie G, Loiseau P, Tamouza R, Janin A, Busson M, Gluckman E et al Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001; 72: 699-706.
8. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003; 3: 53-61.
9. Jones RB, Matthes S, Cagnoni P. Pharmacokinetics. In: Armitage JO, Antman KH (eds). High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, 3rd edn, Lippincott Williams and Wilkins: Philadelphia, 2000, pp 49-68.
10. Grenet O, Bobadilla M, Chibout SD, Steiner S. Evidence for the impairment of the vitamin D activation pathway by cyclosporine A. Biochem Pharmacol 2000; 59: 267-272.
11. Morariu-Zamfir R, Rocha V, Devergie A, Socie G, Ribaud P, Esperou H. et al. Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant 2001; 27 575-580.
12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
13. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U et al Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
14. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y, Kamataki T. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 2001; 281: 1256-1260.
15. Lee KA, Kim SH, Woo HY, Hong YJ, Cho HC. Increased frequencies of glutathione S-transferase (GSTM1 and GSTT1) gene deletions in Korean patients with acquired aplastic anemia. Blood 2001; 98: 3483-3485.
16. Wilson MH, Grant PJ, Hardie LJ, Wild CP. Glutathione Stransferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J 2000; 14: 791-796.
17. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrugresistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
18. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
19. Franco RF, Morelli V, Lourenco D, Maffei FH, Tavella MH, Piccinato CE et al. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease. Br J Haematol 1999; 105: 556-559.
20. Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995; 13: 1103-1109.
21. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
22. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
23. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
24. Coughlin SS, Hall IJ. Glutathione S-transferase polymorphisms and risk of ovarian cancer: A HuGE review. Genet Med 2002; 4: 250-257.
25. Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res 1999; 436: 227-261.
26. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK et al. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-1051.
27. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555-564.
28. Riggs BL. Vitamin D-receptor genotypes and bone density. N Engl J Med 1997; 337: 125-126.
29. Videman T, Leppavuori J, Kaprio J, Battie MC, Gibbons LE, Peltonen L et al. Intragenic polymorphisms of the vitamin D receptor gene associated with intervertebral disc degeneration. Spine 1998; 23: 2477-2485.
30. Hennig BJ, Parkhill JM, Chapple IL, Heasman PA, Taylor JJ. Association of a vitamin D receptor gene polymorphism with localized early-onset periodontal diseases. J Periodontol 1999; 70: 1032-1038.
31. Roy S, Frodsham A, Saha B, Hazra SK, Mascie-Taylor CG, Hill AV. Association of vitamin D receptor genotype with leprosy type. J Infect Dis 1999; 179: 187-191.
32. Gray RJ. A class K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 116: 1141-1154.
33. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
34. Hurvich CM. Regression and time series model selection in small samples. Biometrika, Vol. 76 1989, pp 297-307.
35. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and 'individualized drug therapy': High expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3: 361-370.
36. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000; 59: 961-972.
37. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048.
38. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300: 361-366.
39. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M et al. Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574-1577.
40. Morrow CS, Smitherman PK, Townsend AJ. Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol Carcinog 2000; 29: 170-178.
41. Dusinska M, Ficek A, Horska A, Raslova K, Petrovska H, Vallova B et al. Glutathione S-transferase polymorphisms influence the level of oxidative DNA damage and antioxidant protection in humans. Mutat Res 2001; 482: 47-55.
42. Ouaissi A, Ouaissi M, Sereno D. Glutathione S-transferases and related proteins from pathogenic human parasites behave as immunomodulatory factors. Immunol Lett 2002; 81: 159-164.
43. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J et al Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231-234.
44. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001; 10: 433-443.
45. Evans WE. Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. Pharmacogenetics 2002; 12: 181-182.
46. Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, Oppenraaij-Emmerzaal D et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 79-84.
47. Kim I, Lee KH, Kim JH, Ra EK, Yoon SS, Hong YC et al. Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Ann Hematol 2007; 86: 41-48.
48. Robien K, Schubert MM, Chay T, Bigler J, Storb R, Yasui Y et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 799-800.
49. Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 2006; 37: 773-779.
50. Robien K, Bigler J, Yasui Y, Potter JD, Martin P, Storb R et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2006; 12: 973-980.
51. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
52. Robien K, Ulrich CM, Bigler J, Yasui Y, Gooley T, Bruemmer B et al Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res 2004; 10: 7592-7598.
53. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284-287.
54. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338 143-156.
55. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy -le-grand) 2003; 49: 277-300.
56. Pakkala I, Taskinen E, Pakkala S, Raisanen-Sokolowski A. MC1288, a vitamin D analog, prevents acute graft-versus-host disease in rat bone marrow transplantation. Bone Marrow Transplant 2001; 27: 863-867.
57. Middleton PG, Cullup H, Dickinson AM, Norden J, Jackson GH, Taylor PR et al. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30 223-228.
58. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 6800-6805.
59. Veldman CM, Cantorna MT, Deluca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000; 374: 334-338.